
Image Source: pexels
Many investors share a common confusion: why does the SSE Composite sometimes surge, yet their China funds barely move? This discrepancy stems from different index compilation rules and market representativeness. To clear this up, start with a simple analogy.
Think of the CSI 300 as the “national team of China’s top-performing stocks.” In contrast, the SSE Composite is the “report card of every company listed in Shanghai.”
This metaphor helps quickly grasp the core distinction between the two.

Image Source: unsplash
After understanding the analogy, let’s dive deeper into their fundamental differences in compilation methodology and market representation. These differences are the key reasons their performance often diverges.
The CSI 300 Index, officially named the China Securities Index 300, is compiled by China Securities Index Co., Ltd. Its status is comparable to the U.S. stock market’s S&P 500 — the flagship benchmark reflecting the core dynamics of the Chinese economy.
It selects the 300 largest and most liquid companies from both the Shanghai and Shenzhen stock exchanges. These 300 companies together account for roughly 60% of the total market capitalization of both markets, giving the index strong representativeness.
Smart Weighting Method: Free-Float Market Cap Weighted The CSI 300 uses a free-float adjusted market capitalization weighting method. In simple terms, it only counts shares that are actually tradable in the market. This approach excludes non-tradable shares held long-term by the government or major shareholders, thereby more accurately reflecting real supply-demand dynamics and price movements of tradable stocks.
To give investors a concrete picture, here are the top 10 constituents by weight in the CSI 300:
Historical performance also demonstrates both volatility and growth potential of this key index.
| Year | Percentage Change |
|---|---|
| 2015 | 5.58% |
| 2016 | -11.28% |
| 2017 | 21.78% |
| 2018 | -25.31% |
| 2019 | 36.07% |
| 2020 | 27.21% |
| 2021 | -5.20% |
| 2022 | -21.63% |
| 2023 | -11.38% |
| 2024 | 14.68% |
The SSE Composite Index, officially the Shanghai Stock Exchange Composite Index, is the oldest stock index in China. It includes every stock listed on the Shanghai Stock Exchange, aiming to reflect the overall performance of the Shanghai market.
However, its compilation methodology has notable limitations. The SSE Composite uses total market capitalization weighting, meaning it counts the full market cap of a company (including both tradable and non-tradable shares). This leads to several issues:
In summary, while the SSE Composite remains an important gauge of market sentiment, its structural flaws make it less comprehensive than more modern indices when representing overall economic health.

Image Source: unsplash
Beyond the most frequently mentioned CSI 300 and SSE Composite, China’s stock market has several other important indices. Understanding them helps investors track different market segments more comprehensively.
The SSE 50 Index selects the 50 largest and most liquid companies from the Shanghai Stock Exchange. These are the absolute leaders among blue-chips, representing the core assets of the Shanghai market.
Watching the SSE 50 is like watching a team of superstars. Their massive size gives them enormous market influence.
| Category | Amount (RMB) | Date |
|---|---|---|
| Market Cap | 14.010 trillion | Sep 2017 |
| Free-Float Market Cap | 4.567 trillion | Sep 2017 |
The CSI 500 Index has an interesting selection logic. It first excludes the 300 companies in the CSI 300, then picks the next 500 largest by market cap from the remaining universe. Thus, it primarily reflects the performance of mid- and small-cap companies in China. Compared to large blue-chips, these companies typically offer higher growth potential and represent economic vitality and innovation. The CSI 500 is a key tool for capturing emerging market forces.
The Shenzhen Stock Exchange is the hub for China’s technology and startup companies. The Shenzhen Component Index reflects the overall performance of this market. The ChiNext Index, however, is the spotlight — specifically designed for high-tech and innovative enterprises with relatively flexible listing requirements.
This design makes ChiNext the key indicator for tracking Chinese tech stocks. For example, as of August 2025, the ChiNext Index was up 29.55% year-to-date, demonstrating its high-growth nature.
Once you understand the characteristics of different indices, you can choose the right one based on your investment objectives. Different indices correspond to different strategies and risk appetites.
For investors who prefer stability and want exposure to China’s core assets, the CSI 300 is the primary benchmark. It gathers the 300 largest and most liquid blue-chip companies in China, covering key sectors such as finance, consumer goods, and technology.
Following the CSI 300 is equivalent to locking your focus on the backbone enterprises of the Chinese economy. These companies generally have stable profitability and strong risk resistance, making them ideal for long-term value-growth strategies.
Despite its representativeness limitations, the SSE Composite’s long history and broad coverage make it an important thermometer for overall market sentiment and liquidity. When media reports say “Chinese stocks surged,” they usually refer to the SSE Composite.
Thus, investors can use the SSE Composite as a macro reference to gauge short-term market heat and policy direction, but for precise stock or sector investing, it should be combined with more specific indices.
If your goal is to capture explosive new ventures, the ChiNext Index is undoubtedly the focus. It concentrates on high-tech and innovative companies, representing China’s new economic transformation drivers. However, high return potential comes with high risk.
A financial health assessment of ChiNext-listed companies shows significant financial risks exist when investing in these firms.
| Financial Health Rating | Number of Companies | Percentage |
|---|---|---|
| Healthy | 34 | 6.76% |
| Near Healthy | 218 | 43.34% |
| Sub-Healthy | 156 | 31.01% |
| Unhealthy | 95 | 18.89% |
| Total | 503 | 100% |
The data shows only a very small portion are rated financially healthy. International investors wanting exposure can diversify risk through financial instruments such as ChiNext-tracking ETFs. Some platforms (e.g., Biyapay) and traditional brokers offer access to these assets.
In conclusion, thanks to its cross-market coverage and blue-chip focus, the CSI 300 better represents the core strength of the Chinese economy. For value investors, it is the more meaningful benchmark.
Spending one extra minute understanding index rules before investing is the first step to making the right decisions. This effectively prevents the embarrassment of “watching the wrong index and buying the wrong asset,” making your investment strategy far more precise.
The CSI 300 is the more representative benchmark. It spans both Shanghai and Shenzhen markets and uses free-float market cap weighting, more accurately reflecting the true value of top-performing stocks.
This usually happens because your fund tracks a different index — not the SSE Composite. Many China-focused funds track the CSI 300, which better reflects blue-chip performance, so their movements often differ.
Beginners are recommended to start with the CSI 300. It includes the most important group of leading companies in the Chinese market, helping build a foundational understanding of core assets and serving as an excellent starting point for grasping Chinese economic trends.
No. Index providers conduct regular reviews, typically semi-annually. They remove companies that no longer meet criteria and add new qualifying ones to ensure the index continues to reflect the latest market conditions.
*This article is provided for general information purposes and does not constitute legal, tax or other professional advice from BiyaPay or its subsidiaries and its affiliates, and it is not intended as a substitute for obtaining advice from a financial advisor or any other professional.
We make no representations, warranties or warranties, express or implied, as to the accuracy, completeness or timeliness of the contents of this publication.



